Safety and Efficacy of FIT039 for Verruca Vulgaris: A Placebo-Controlled, Phase I/II Randomized Controlled Trial
Trial design: Human papillomavirus infection causes verruca vulgaris. CDK9 inhibitor FIT039 inhibits DNA virus proliferation in animal models. We conducted a multicenter, single-blind, placebo-controlled, randomized phase I/II clinical trial evaluating the safety and efficacy of FIT039 against verru...
Tallennettuna:
Päätekijät: | , , , , , , , , , , , , , , , , , , |
---|---|
Aineistotyyppi: | Kirja |
Julkaistu: |
Elsevier,
2021-09-01T00:00:00Z.
|
Aiheet: | |
Linkit: | Connect to this object online. |
Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|
Internet
Connect to this object online.3rd Floor Main Library
Hyllypaikka: |
A1234.567 |
---|---|
Nide 1 | Saatavissa |